NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology

Core Points - NKGen Biotech, a clinical-stage biotechnology company, is focused on developing innovative NK cell therapeutics and will present at the XXVII World Congress of Neurology in Seoul, South Korea from October 12-15, 2025 [1][2] - The presentation will highlight the scientific rationale and clinical findings for troculeucel, an investigational autologous NK cell therapy aimed at treating Alzheimer's disease, demonstrating the company's commitment to advancing neurological care [2][3] Company Overview - NKGen Biotech is headquartered in Santa Ana, California, and specializes in the development and commercialization of autologous and allogeneic NK cell therapeutics [5] - Troculeucel, the company's novel cell-based immunotherapeutic drug candidate, is designed for treating neurodegenerative disorders and various cancers, with its International Nonproprietary Name (INN) assigned as SNK01 by the WHO [4] Presentation Details - The presentation titled "Expanded Non-genetically Modified Natural Killer Cells (Troculeucel) with Enhanced Cytotoxicity in Moderate/Advanced Alzheimer's Disease" will be delivered by Paul Y. Song, M.D. on October 15, 2025, at 11:50 AM KST [3] - The session will focus on ataxia, cerebellar disorders, and dementia, and a copy of the presentation will be available on the company's website post-event [3]